Merck KGaAXSWX:MER +4.03%83 Days Payable is 79.10 as of Mar. 2026, which is 2% above its 10-year median of 77.76. GuruFocus rates XSWX:MER with a GF Score™ of 83/100 and a GF Value™ of CHF125.76. The stock has 9 warning signs investors should review. Among 920 Drug Manufacturers companies, Merck KGaA ranks worse than 57.07% on this metric.
Merck KGaA's average Accounts Payable for the
three
months ended in Mar. 2026 was CHF1,632 Mil. Merck KGaA's Cost of Goods Sold for the
three
months ended in Mar. 2026 was CHF1,883 Mil.
Hence, Merck KGaA's Days Payable for the
three
months ended in Mar. 2026 was 79.10.
The historical rank and industry rank for Merck KGaA's Days Payable or its related term are showing as below:
XSWX:MER'
s Days Payable Range Over the Past 10 Years
Min: 60.94 Med: 77.76 Max: 116.08
Current: 80.06
During the past 13 years, Merck KGaA's highest Days Payable was 116.08. The lowest was 60.94. And the median was 77.76.
XSWX:MER's Days Payable is ranked worse than 57.07% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs XSWX:MER: 80.06
Merck KGaA's Days Payable
increased
from Mar. 2025 (76.08) to Mar. 2026 (79.10).
It may suggest that Merck KGaAdelayed paying its suppliers.
Merck KGaA Days Payable Related Terms
Merck KGaA Days Payable Historical Data
* Premium members only.
The historical data trend for Merck KGaA's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:MER vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Merck KGaA's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merck KGaA Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Merck KGaA's Days Payable distribution charts can be found below:
* The bar in red indicates where Merck KGaA's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Merck KGaA's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merck KGaA (XSWX:MER) has a Days Payable of 79.10 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Merck KGaA and its competitors. This is near median its historical median of 77.76. Over the past decade, Merck KGaA's Days Payable has ranged from 60.94 to 116.08. According to the industry distribution chart, Merck KGaA ranks #525 out of 920 companies in the Drug Manufacturers industry, placing it in the top 57.1%.
Is Merck KGaA's Days Payable too high?
Merck KGaA's current Days Payable of 79.10 is near median its 10-year median of 77.76. Over the past 10 years, this metric has ranged from a low of 60.94 to a high of 116.08. The Drug Manufacturers industry median Days Payable is 90.84. Merck KGaA's value of 79.10 is 12.9% below this industry median. Based on the distribution chart, Merck KGaA ranks #525 out of 920 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Merck KGaA has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Merck KGaA ranks #525 out of 920 companies for Days Payable. This places Merck KGaA in the lower half of its industry. The industry median Days Payable is 90.84. Merck KGaA's value of 79.10 is 12.9% below this benchmark. Historically, Merck KGaA's own Days Payable has ranged from 60.94 to 116.08 over the past decade. While the company's 10-year median is 77.76 vs. the industry median of 90.84, Merck KGaA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Merck KGaA's current Days Payable of 79.10 is 12.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Merck KGaA and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Merck KGaA's current Days Payable is 79.10, which is near median its own 10-year median of 77.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Merck KGaA (XSWX:MER) has a current Days Payable of 79.10. The stock's GF Value™ is CHF125.76, compared to a current price of CHF130.30 — trading 3.6% above its estimated fair value. The current Days Payable is 79.10, which is near median its 10-year median of 77.76 and 12.9% below the Drug Manufacturers industry median of 90.84. Merck KGaA's overall GF Score™ is 83/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Merck KGaA (XSWX:MER), the current Days Payable is 79.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Merck KGaA (XSWX:MER) Overvalued in 2026?
Based on GuruFocus' analysis, Merck KGaA stock appears to be overvalued.
The current stock price of CHF130.30 is trading 3.6% above its estimated GF Value™ of CHF125.76.
Key valuation signals for XSWX:MER:
Days Payable: 79.10 (near median its 10-year median of 77.76)
GF Value™: CHF125.76 vs. price of CHF130.30 (3.6% above fair value)
Industry Position: 12.9% below the Drug Manufacturers median (#525 of 920)
No single metric tells the full story. See the XSWX:MER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
83GF Score
Get the complete analysis for XSWX:MER
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MER has been successfully added to your 
